Hindustan Laboratories IPO Analyzed

Hindustan Laboratories, a company that makes generic medicines, is planning to go public. They’ve submitted a plan called a “red herring prospectus” to the government’s stock market regulator, Sebi. This means they want to sell shares to the public for the first time.

Key Points

• Hindustan Labs is seeking to raise funds through an IPO.
• 5 million new shares and 9.1 million shares will be offered.
• Rajesh Doshi, a key owner, will sell some of his stake.
• Funds will be used for operations and general company expenses.
• Financials show strong growth in revenue and profitability.
• Focus on supplying affordable medicines to government healthcare systems.

About the IPO

The IPO will involve two parts: a fresh issue of 5 million shares and an “offer for sale” (OFS) of 9.1 million shares. This means the company is selling existing shares held by its owner, Rajesh Vasantray Doshi. The money raised will be used to help the company run smoothly and for other important business activities.

Financial Performance

Hindustan Laboratories has been growing its business. In the six months ending September 30, 2025, they made ₹112.63 crore in sales and earned ₹18.2 crore in profit. The company’s revenue jumped 17.9% to ₹219.74 crore in the last fiscal year.

EBITDA and Profits

Their “EBITDA,” which is a way to measure how profitable the company is before certain costs, increased to ₹53.87 crore. This is up 22.18% from the previous year. Their profit after tax also increased to ₹41.26 crore, compared to ₹34.13 crore.

What Hindustan Laboratories Does

Hindustan Laboratories makes generic medicines, which are medicines that aren’t protected by patents. They primarily sell these to the government through contracts. These contracts help the government provide affordable healthcare.

They produce a wide range of medicines, including those for allergies, diabetes, infections, and various other health conditions. This includes nutritional supplements, pain relievers, and vitamin products.

“This IPO presents a significant opportunity for investors to support a growing company supplying essential medicines to the Indian healthcare system.”